Tobacco Online Policy Seminar (TOPS) October 7, 2022

Varenicline Plus Counseling for Smoking Cessation in African Americans

Lisa Sanderson Cox, PhD

Professor, Department of Population Health University of Kansas School of Medicine

The University of Kansas

CANCER CENTER





JAMA | Original Investigation

2022;327(22):2201-2209.

Effect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers The Kick It at Swope IV Randomized Clinical Trial

Lisa Sanderson Cox, PhD; Nicole L. Nollen, PhD; Matthew S. Mayo, PhD; Babalola Faseru, MD, MPH; Allen Greiner, MD; Edward F. Ellerbeck, MD, MPH; Ron Krebill, MPH; Rachel F. Tyndale, PhD; Neal L. Benowitz, MD; Jasjit S. Ahluwalia, MD, MPH How can advances in tobacco treatment and policy advance health equity?





THE UNIVERSITY OF KANSAS

CANCER CENTER

Acknowledgements:

University of Kansas School of Medicine Nikki L. Nollen, PhD Matthew M. Mayo, PhD Edward Ellerbeck, MD, MPH Babalola Faseru, MD, MPH Won Choi, MD, MPH Taneisha Scheuermann, PhD Tricia Snow, MPH Ron Krebill, MPH Allen Greiner, MD

Teri Tapp, Sherri Anderson, MA Brian Hernandez, Edward Liebmann, PhD°

National Institutes of Health National Institute on Drug Abuse

<u>Pfizer Global Medical Grants</u> Providing varenicline and placebo

Conflicts of Interest: None

Collaborations


Jasjit S. Ahluwalia, MD, MPH, Brown University Neal Benowitz, MD, University of California, San Francisco Rachel Tyndale, PhD, University of Toronto Kolawole Okuyemi, MD, MPH, University of Utah



Community Engagement:

- Swope Health Services
- Community Advisory Board
- Congressman, Rev. Emanuel Cleaver II
- Black Healthcare Coalition
- Black Chamber of Commerce
- American Jazz Museum
- Negro Leagues Baseball Museum
- The National WWI Museum and Memorial
- Union Station
- YMCA of Kansas City










FOR YOUTH DEVELOPMENT® FOR HEALTHY LIVING FOR SOCIAL RESPONSIBILITY

SWOPE HEALTH

THE UNIVERSITY OF KANSAS

CANCER CENTER









BLACK CHAMBER OF COMMERCE

University of Kansas Medical Center – Swope Health Collaborative Kick It at Swope (KIS) and Quit2Live (Q2L) smoking cessation studies:

Funding Agency	Grant Title	PI
National Cancer Institute RO1 CA77856	Does bupropion help African Americans quit smoking? (KIS-I)	Jasjit S. Ahluwalia
National Cancer Institute R01 CA85930	African Americans smokers in low income housing (Pathways to Health)	Jasjit S. Ahluwalia
National Cancer Institute R01 CA091912	Helping African American light smokers quit (KIS-II)	Jasjit S. Ahluwalia
National Cancer Institute R01 CA091912	Enhancing tobacco use treatment for African American light smokers (KIS-III)	Lisa Sanderson Cox
National Institute on Drug Abuse R01 DA031815	Understanding disparities in quitting in African American and White smokers (Q2L)	Nicole Nollen
National Institute on Drug Abuse R01DA035796	Advancing tobacco use treatment for African American smokers (KIS-IV)	Lisa Sanderson Cox
PCORI AD-1310-08709	Informing tobacco-treatment guidelines for African American non-daily smokers (Q2L ²)	Nicole Nollen
National Institute on Drug Abuse R01 DA046576	Individualizing Pharmacotherapy: A novel optimization strategy to increase smoking cessation in the African American community (Q2L ³⁾	Nicole Nollen
National Cancer Institute R01 CA259256	Improving smoking abstinence outcomes in the African American community through extended treatment (KIS-V)	Lisa Sanderson Cox
National Institute on Drug Abuse R01 DA055999	The impact of menthol flavoring on switching in adult menthol smokers	Nicole Nollen















Share of Nonelderly Population that is a Person of Color



Tremendous progress at reducing smoking rate but 34 million America adults still smoke



Cigarette smoking is down, but about 34 MILLION American adults still smoke

Cigarette smoking remains high among certain groups



Adults 25-64 years old

Disabled



Lower education



Below poverty level



Midwest and South

Higher rates of tobacco use

- < high-school education (23%)
- live ≤ 100% FPL (21%)
- receive Medicaid (25%)
- have serious psychological distress (35%)
- identify as lesbian, gay, or bisexual (20%)
- racial/ethnic minorities (7%-23%)



Uninsured or Medicaid




Serious psychological distress



American Indians, Alaska Natives and Multiracial

Lesbians, gays, and bisexuals



Major Conclusions


- 1. Addressing TRHD is necessary to reduce the disease burden of tobacco use.
- 2. Some groups have benefited less from efforts to reduce tobacco use.
 - racial and ethnic minorities
 - light smokers
- 3. Broader implementation of known effective strategies to reduce tobacco use would contribute substantially to reducing TRHD.

U.S. Department of Health & Human Services | National Institutes of Health

U.S. National Cancer Institute. A Socioecological Approach to Addressing Tobacco-Related Health Disparities. National Cancer Institute Tobacco Control Monograph 22. NIH Publication No. 17-CA-8035A. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2017. cancercontrol.cancer.gov/brp/tcrb/monographs/22/index.html

African American Smokers

- Prevalence similar to non-Hispanic Whites
- Start smoking later
- Try to quit smoking more often
- High relapse rate
- More likely to smoke menthol cigarettes
- Higher cotinine levels per cigarette
- Smoke fewer cigarettes per day
- Have highest cancer incidence and morbidity





Original Investigation | Substance Use and Addiction

Assessment of Racial Differences in Pharmacotherapy Efficacy for Smoking Cessation Secondary Analysis of the EAGLES Randomized Clinical Trial

Nicole L. Nollen, PhD; Jasjit S. Ahluwalia, MD; Lisa Sanderson Cox, PhD; Kolawole Okuyemi, MD; David Lawrence, PhD; Larry Samuels, PhD; Neal L. Benowitz, MD

Abstract


IMPORTANCE Understanding Black vs White differences in pharmacotherapy efficacy and the underlying reasons is critically important to reducing tobacco-related health disparities.

OBJECTIVE To compare pharmacotherapy efficacy and examine variables to explain Black vs White differences in smoking abstinence.

Key Points

Question Does the efficacy of varenicline, bupropion, and nicotine patch differ for US Black and White smokers, and what variables explain the difference?

Nollen et al., 2021, JAMA Network Open



Nollen et al., 2021, JAMA Network Open

Nollen et al., 2021 Assessment of racial differences...EAGLES secondary analysis

Conclusions:

- Black moderate to heavy smokers significantly less likely than Whites to achieve abstinence
 - Varenicline only pharmacotherapy demonstrating efficacy over placebo for Black participants
- Limitations
 - No evaluation of key factors, e.g., menthol, metabolism, socioeconomic status¹
 - No light smokers

➢ Race is a proxy for social, contextual, and biological differences (Nollen et al., 2019)

- Studies needed to identify <u>why</u> i.e., what mechanisms
 - Nollen NL, Mayo MS, Cox LS, et al. Factors that Explain Differences in Abstinence between Black and White Smokers: A Prospective Intervention Study. *JNCI: Journal of the National Cancer Institute*. 2019. doi:10.1093/jnci/djz001.

KIS-IV



- Primary Aim:
 - To evaluate the efficacy of varenicline versus placebo for tobacco use treatment. Main outcome was cotinine-confirmed 7-day abstinence at Month 6.

• Design:

- Randomized placebo-controlled trial of 12 weeks varenicline among 500 African American daily smokers (300 to varenicline, 200 to placebo) including light, moderate, and heavy daily smokers.
 - 3:2 randomization stratified by sex and cigarettes per day (1-10cpd or >10cpd)
- Culturally relevant, individually tailored, cognitive behavioral counseling and health education for all participants.

KIS-IV Eligibility Criteria

- Self-identified African American
- \geq 18 years of age
- Smokes <u>></u>1cpd
- Smoke on <u>></u>25 days of the past 30 days
- Functioning telephone
- Interested in quitting smoking
- Interested in taking varenicline for 12 weeks
- Willing to complete all study visits
- Medication approval from physician

•	Renal	impairm	ent
---	-------	---------	-----


• Evidence or history of clinically significant allergic reactions to varenicline

Exclusion Criteria


- A cardiovascular event in the past month
- History of alcohol or drug dependence in the past year
- Major depressive disorder in the last year requiring treatment
- History of panic disorder, psychosis, bipolar disorder, or eating disorders
- Use of tobacco products other than cigarettes in past 30 days
- Use of smoking cessation pharmacotherapy in the month prior to enrollment, including varenicline
- Pregnant, contemplating getting pregnant, or breastfeeding
- Plans to move from KC during the treatment and follow-up phase
- Another household member enrolled in the study

KIS-IV CONSORT Diagram

Community and clinic-based recruitment.



KIS-IV Flowchart



Medication given at Weeks 0, 4, 8. Retention: (%) completed scheduled visit within window.

KIS-IV Participants n=500

- Average age = 52 years
- 52% female
- \$27,600 total gross income
- 86% > high school education
- 27% married or living with partner
- 65% covered by health insurance

KIS-IV Participants n=500

- Cigarettes per day, mean (SD) = 12.6 (6.6)
- 52% light smokers (1-10 cpd)
- 79% smoked within 30 min. of waking
- 86% smoked menthol cigarettes
- 26% lived in smoke-free home
- 80% attempted to quit in past year
- Number of quit attempts in past year = 1.9
- 48% past use of pharmacotherapy to quit
- 22% past use of varenicline to quit

KIS-IV Cotinine-verified 7-day Abstinence

	Varenicline	Placebo	Odds	P value
	n=300	n=200	(95% CI)	
Quit at Week 4	16.00 %	5.00 %	3.62 (1.79-7.34)	0.0002
Quit at Week 12	18.67 %	7.00 %	3.04 (1.65-5.64)	0.0002
Quit at Week 16				
Quit at Week 26				

Cotinine verified (< 15ng/ml).

Those lost to follow-up were treated as smokers.

KIS-IV Cotinine-verified 7-day Abstinence

	Varenicline n=300	Placebo n=200	Odds (95% CI)	P value
Quit at Week 4	16.00 %	5.00 %	3.62 (1.79-7.34)	0.0002
Quit at Week 12	18.67 %	7.00 %	3.04 (1.65-5.64)	0.0002
Quit at Week 16	18.00 %	6.50 %	3.16 (1.67-5.96)	0.0002
Quit at Week 26	15.67 %	6.50 %	2.67 (1.40-5.08)	0.0020


Cotinine verified (< 15ng/ml).

Those lost to follow-up were treated as smokers.

KIS-IV Cotinine-verified 7-day Abstinence


Light Smokers (1-10 cpd)





Cotinine verified (< 15ng/ml). Those lost to follow-up were treated as smokers.

Prevalence of biochemically verified 7-day point prevalence smoking abstinence



Cox et al., JAMA, 2022

KIS-IV Varenicline Side Effects

Prevalence of cumulative adverse events by symptom and globally by treatment, No. (%)					
	By Sy	mptom, Weeks	5 1-16		
	Placebo	Varenicline	(p)		
	n=196	n=293			
Change in hostility or aggression	79 (40.3)	99 (33.8)	.14		
Fatigue or loss of energy	112 (57.1)	163 (55.6)	.74		
Nausea	90 (45.9)	163 (55.6)	.03		
Trouble sleeping	117 (59.7)	190 (64.8)	.25		
Headaches	95 (48.5)	157 (53.6)	.27		
Abnormal dreams	93 (47.4)	146 (49.8)	.60		
Gas or flatulence	130 (66.3)	191 (65.2)	.79		
Constipation	78 (39.8)	120 (41.0)	.80		
Dizziness	62 (31.6)	95 (32.4)	.85		
Dry mouth	129 (65.8)	183 (62.5)	.45		
Irritability	111 (56.6)	167 (57.0)	.94		
Global, Weeks 1-16					
Any	178 (90.8)	276 (94.2)	.15		
SAE	2 (1.0)	0 (0.0)	**		

Prevalence of cumulative adverse events by symptom and globally by treatment, No. (%)

**Sparse events No (p) provided.

What accounts for treatment effect?

- No difference between treatment groups in
 - session attendance / retention
 - self-reported medication adherence
 - change in psychological reward from smoking (mCEQ)
 - change in withdrawal symptoms (MNWS)
 - change in craving (QSU-Brief)

KIS-IV Summary

- Varenicline was effective in promoting short (EOT Week 12) and long-term (Month 6) abstinence in African American daily smokers.
 - Varenicline treatment outcomes replicate Quit2Live (Nollen et al, 2019, JNCI)
- Varenicline was effective in promoting abstinence in light smokers and in moderateheavy smokers.
- Varenicline was safe and well-tolerated
 - Reported side effects were similar between active and placebo groups.
 - Nausea was only symptom reported more frequently in active group.
 - Counseling for medication management
- The need to enhance treatment for African Americans remains.
 - KIS-V will examine extended (24 weeks) varenicline treatment.

Kick It at Swope – Quit2Live

Over 20 years of tobacco treatment research in the African American community - > 3,200 participants



- African Americans benefit from pharmacotherapy within tobacco treatment
- African American smokers are highly engaged in treatment and successful at quitting across therapies. Across studies:
 - > 80% return for study visits
 - Good compliance to medication (w/exception of gum)
 - 13%-24% still quit at month 6
 - Chance of quitting 50%-200% higher with medication relative to placebo
- Non-nicotine medications (VAR, BUP) may be preferable
 - Adherence is central to success
- Varenicline for treatment of light smokers
 - Non-daily smokers may benefit from pharmacotherapy support
- Continued efforts needed to enhance efficacy of existing medications
 - Extended treatment, changing pharmacotherapy, repeated intervention

Tobacco Online Policy Seminar (TOPS) – October 7, 2022

Discussion

LCox@kumc.edu





THE UNIVERSITY OF KANSAS

CANCER CENTER

How can advances in tobacco treatment and policy advance health equity?






Access and cost

Access and cost

Uninsured Rates for the Nonelderly Population by Race and Ethnicity, 2010-2019



NOTE: Includes individuals ages 0 to 64. AIAN refers to American Indians and Alaska Natives, NHOPI refers to Native Hawaiians and Other Pacific Islanders. Persons of Hispanic origin may be of any race but are categorized as Hispanic for this analysis; other groups are non-Hispanic SOURCE: KFF analysis of the 2010-2019 American Community Survey.

Access and cost

- nicotine replacement patch
 - \$56-\$81 for 4 weeks (\$2.45/day)
- generic bupropion
 - \$58-\$92 for 4 weeks (\$2.68/day)
- generic varenicline
 - \$398-\$494 for 4 weeks (\$15.93/day)

=\$1,194 - \$1,482 for 12 weeks of treatment

How can advances in tobacco treatment and policy advance health equity?





THE UNIVERSITY OF KANSAS CANCER CENTER

Tobacco Online Policy Seminar (TOPS) – October 7, 2022

Discussion

LCox@kumc.edu





THE UNIVERSITY OF KANSAS

CANCER CENTER

SRNT-University

SRNT University SRNT University

srnt-u.org

WELCOME TO SRNT-U, a collection of organized, curated training, scientific articles, and tools and resources for people working in nicotine and tobacco research and related professions. Questions or comments? Email us

- Smoking Cessation Research Certificate Program
- Themed collections
- Methodology courses
- Webinars and podcasts
- Tools and resources



BROWSE THE SRNT-U LIBRARY



BROWSE THE SRNT-U CLASSROOM



Library Section: Preclinical Research



Library Section: Clinical Research



Library Section: Public Health Research



Library Section: Policy Research



Library Section: Health Disparities

INDIGENOUS RESEARCH

Library Section: Indigenous Research



Library Section: Menthol Tobacco



Library Section: Heated Tobacco Products



Library Section: E-cigarette Collection



eTable 2. Week 26 self-report and verified 7-day point prevalence smoking abstinence

	Trea	Treatment	
	Varenicline	Placebo	P value
A) Number of participants randomized	300	200	
B) Number of participants who completed Week 26 visit (B/A)	267 (89.0%)	174 (87.0%)	NA
C) Self-reported completers only abstinence at Week 26 (C/B)	114 (42.7%)	64 (36.8%)	NA
D) Verification samples obtained at Week 26 (D/C)	109 <mark>(</mark> 95.6%)	62 (96.9%)	NA
E) Verified abstinence for completers only (E/B)	47 (17.6%)	13 (7.5%)	0.002
F) Verified abstinence using Russel Standard* (F/A)	47 (15.7%)	13 (6.5%)	0.002
G) Verified abstinence using Last Observation Carried Forward	71 (23.7%)	19 (9.5%)	<0.001
H) Verified abstinence using Multiple Imputation**	69.2 (23.1%)	27.8 (13.9%)	0.02
*Participants with missing data imputed as smoking			
**Average of 100 imputations assuming monotonic logistic regre	ession with treatr	ment and smoki	ng level



JAMA | Original Investigation

Effect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers The Kick It at Swope IV Randomized Clinical Trial

Lisa Sanderson Cox, PhD; Nicole L. Nollen, PhD; Matthew S. Mayo, PhD; Babalola Faseru, MD, MPH; Allen Greiner, MD; Edward F. Ellerbeck, MD, MPH; Ron Krebill, MPH; Rachel F. Tyndale, PhD; Neal L. Benowitz, MD; Jasjit S. Ahluwalia, MD, MPH

R01 DA035796: Advancing Tobacco Use Treatment for African American Smokers

Cox, Nollen, Mayo et al. JAMA. 2022;327(22):2201–2209.